title: p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.
abstract: Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 and show "gain of function" (GOF) phenotypes such as increased growth rate, enhanced resistance to chemotherapeutic drugs, increased cell motility and tumorigenicity; although the mechanism for this function remains unknown. In this communication we report that p53-mediated NF-κB2 up-regulation significantly contributes to the aggressive oncogenic behavior of cancer cells. Lowering the level of mutant p53 in a number of cancer cell lines resulted in a loss of GOF phenotypes directly implicating p53 mutants in the process. RNAi against NF-κB2 in naturally occurring cancer cell lines also lowers GOF activities. In H1299 cells expressing mutant p53, chromatin immunoprecipitation (ChIP) assays indicate that mutant p53 induces histone acetylation at specific sites on the regulatory regions of its target genes. ChIP assays using antibodies against transcription factors putatively capable of interacting with the NF-κB2 promoter show increased interaction of CBP and STAT2 in the presence of mutant p53. Thus, we propose that in H1299 cells, mutant p53 elevates expression of genes capable of enhancing cell proliferation, motility, and tumorigenicity by inducing acetylation of histones via recruitment of CBP and STAT2 on the promoters causing CBP-mediated histone acetylation.
authors.affiliation: Department of Biochemistry & Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, United States.
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Vaughan
authors.forename: Shilpa
authors.initials: S
authors.lastname: Singh
authors.forename: Brad
authors.initials: B
authors.lastname: Windle
authors.forename: Heidi M
authors.initials: HM
authors.lastname: Sankala
authors.forename: Paul R
authors.initials: PR
authors.lastname: Graves
authors.forename: W
authors.initials: W
authors.lastname: Andrew Yeudall
authors.forename: Swati P
authors.initials: SP
authors.lastname: Deb
authors.forename: Sumitra
authors.initials: S
authors.lastname: Deb
mesh_terms: D000107:Acetylation; D000818:Animals; D050882:CREB-Binding Protein / Q000378:metabolism*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D002843:Chromatin / Q000235:genetics / Q000378:metabolism; D006657:Histones / Q000378:metabolism; D006801:Humans; D051379:Mice; D009154:Mutation; D052003:NF-kappa B p52 Subunit / Q000172:deficiency / Q000235:genetics* / Q000378:metabolism; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011485:Protein Binding / Q000235:genetics; D034622:RNA Interference; D050791:STAT Transcription Factors / Q000378:metabolism*; D014158:Transcription, Genetic / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation / Q000235:genetics
chemical_list: D002843:Chromatin; D006657:Histones; D052003:NF-kappa B p52 Subunit; C498206:NFKB2 protein, human; D050791:STAT Transcription Factors; D016159:Tumor Suppressor Protein p53; D050882:CREB-Binding Protein; C494363:CREBBP protein, human